Quality care for your patients taking vitamin K antagonists
Vitamin K antagonists (VKAs) require close monitoring because of individual variations, drug-drug or food-drug interactions. Studies have shown that increasing a patient’s time in therapeutic range, as measured by their international normalised ratio (INR) value, maximises the benefits of anticoagulation therapy and minimises the risk of thromboembolic events.1-3 Therefore, keeping careful track of your patient's INR value to ensure it is in the optimal therapeutic range is critical.